The Alzheimer Society of Ireland (ASI) has welcomed the decision by the European Medicines Agency (EMA) to recommend Leqembi for licensing approval. This follows a re-examination of an earlier decision to not recommend the therapy for approval. The ASI said the decision is, “another step closer to seeing Disease Modifying Therapies for early-stage Alzheimer’s Disease becoming available in the European Union and (we) are optimistic that the European Commission will follow the EMA’s recommendation”.

If approved, this will mark the first Disease Modifying Therapy for Alzheimer’s Disease approved in the EU. The ASI said, “we must work together to accelerate efforts in Ireland to prepare for the arrival of Disease Modifying Therapies while ensuring we build on existing services and supports for those who will not benefit from them”.